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Abstract 
A simple and fast isocratic Reverse Phase High Performance Liquid Chromatography (RP-HPLC) method has 
been developed and validated for the simultaneous determination of Lamivudine, zidovudine and their related 
impurities in tablets. The method consists of a mobile phase combination of Acetonitrile (HPLC grade) and 
Buffer (0.0680 g of Potassium Dihydrogen Orthophosphate, 0.3 ml of Triethylamine, pH adjusted to 8.0 with 
Orthophosphoric acid to a final volume preparation of 100 ml) in the ratio 10:90. Phenomenex Luna 5-µm C18 
(2)-250 x 4.6-mm, 5-µm) was used as the stationary phase. The column oven was set to a temperature of 
30±1oC. Quantification was achieved with a DAD detector set at 270 nm.  
Resolution was achieved at a short run time of 25 minutes. Zidovudine related impurity C, Lamivudine, salicylic 
acid, Zidovudine and Zidovudine related impurity B eluted at 3.749±0.004, 4.862±0.013, 15.332±0.064, 
21.201±0.076 and 23.682±0.117 respectively. Relative retention times (RRT) for lamivudine unknown related 
impurities with respect to Zidovudine were 0.15, 0.17, 0.30 and 0.59. RRT for Zidovudine unknown related 
impurities with respect to Zidovudine were 0.39 and 0.63.  The method was found to be specific, robust, accurate 
and precise for the estimation of Zidovudine related impurity C, Lamivudine, salicylic acid, Zidovudine and 
Zidovudine related impurity B in fixed oral dosage tablets over the concentration ranges of 0.0204 mg/mL-
0.0088 mg/mL, 0.0962 mg/mL-0.7699 mg/mL, 0.1929 mg/mL-1.5410 mg/mL and 0.0088 mg/mL-0.024 mg/mL 
respectively. The Correlation Coefficient (r2) for Zidovudine related impurity C, Lamivudine, salicylic acid, 
Zidovudine and Zidovudine related impurity B were greater than 0.998. The LOD were found to be between 
1.9x10-4 mg/mL to 2.69 x10-4 mg/mL.  The proposed method is precise, specific, accurate and robust for the 
simultaneous estimation of Zidovudine related impurity C, Lamivudine, salicylic acid, Zidovudine, Zidovudine 
related impurity B and other related impurities in dosage forms.  
Keywords: Zidovudine related impurity C, Lamivudine, salicylic acid, Zidovudine, Zidovudine related impurity 
B, Lamivudine related impurities, Zidovudine related impurities RP-HPLC, Validation.  
 
1. INTRODUCTION 
Lamivudine and Zidovudine are synthetic nucleoside analogues with activity against HIV-1. Lamivudine and 
Zidovudine are two nucleoside analogue reverse transcriptase inhibitors. Intracellularly, lamivudine is 
phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode 
of action of 3TC-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of 
the nucleotide analogue. 3TC-TP is a weak inhibitor of cellular DNA polymerases α, β, and γ.[1] It has a 
molecular formula of C8H11N3O3S with a molecular mass 229.26 g/mol. 
Zidovudine once absorbed is phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate 
(ZDV-TP). The principal mode of action of ZDV-TP is inhibition of RT via DNA chain termination after 
incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases α and γ 
and has been reported to be incorporated into the DNA of cells in culture. [1]   
Its molecular formula is, C10H13N5O4 with a molecular mass of 267.24 g 
Few chromatographic methods for the simultaneous determination of lamivudine, Zidovudine and related 
impurities have been reported. Few methods available includes those in the compendia. [2,3] The aim of this study 
is to develop a simple RP-HPLC method in a model tablet formulation containing 150 mg of Lamivudine and 
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300 mg of zidovudine. This study was done in accordance with the International Conference on Harmonization 
(ICH) guidelines [4,5,6,7,8]. 
 
2. MATERIALS AND METHODS  
2.1 Materials and Reagents: 
Chemicals / Reagents: Acetonitrile (Manufacturer: Fisher Scientific, Batch #: 0803950), Hydrochloric Acid (BN: 
H1/65/450-1, Manufacturer: M&B, Purity: 36 %w/w), 2 M sodium hydroxide, 35 % hydrogen peroxide, USP 
Purified Water and Doubly distilled water. 
Analytical Reference Standards: USP Lamivudine (Lot #: H0H087, Potency: 99.6 %), USP Zidovudine RS (Lot 
#: HOF263, Potency: 99.0 %), USP   Zidovudine Related Compound B RS (Lot #: H0F230, Potency: 100.0 %), 
USP Zidovudine Related Compound C RS (Lot #: GOG181, Potency: 100.0 %), Salicylic acid (Lot #: KOF112), 
Potency: 99.8 %). Lamivudine Working standard (Manufacturer: Shanghai Desano Chemical Co. LTD. China, 
Lot #: DH010-4-090405, Potency (OAB): 98.34 %. Zidovudine Working Standard (Manufacturer: Shanghia 
Desano Chemical CO Ltd, Lot #: DH006-4-090430, Potency (OAB): 100.93 %. 
Pharmaceutical Excipients: Microcrystalline cellulose (Batch #: 0028, Manufacturer: Brahmar Cellulose 
Products PVT Ltd, Solutab (Croscamellose Sodium) (Batch #: 8199/09, Manufacturer: Blanver Farmoquimica 
Ltd, Magnesium Stereate (Batch #: MGSV80097, Manufacturer: Stockbridge International Ltd. Aerosil 
(Colloidal Silicon Dioxide) (Batch #: 132700021, Manufacturer: Biochemie. 
 
2.2 Instrumentation and Chromatographic conditions 
Agilent Technologies 1200 series HPLC modules (G1315D, G1315A, G1329A, G1311A, G1332A and organizer, 
with ChemStation data processing software), Sonicator, OHAUS Analytical Balance. Stainless steel column 250 
mm long, 4.6 mm internal diameter filled with Octadecyl silane chemically bonded to porous silica particles of 5 
µm diameter (Phenomenex Luna 5-µm C18 (2)-250 x 4.6-mm, 5-µm). Mobile phase composition was 90(buffer): 
10 Acetonitrile.  Buffer was prepared from 0.0680 g of Potassium Dihydrogen Orthophosphate, 0.3 ml of 
Triethylamine, pH adjusted to 8.0 with Orthophosphoric acid diluted with distilled water to a final volume of 100 
ml. The mobile phase was pumped through the column at a flow rate of 1 mL/minute. The sample injection 
volume was 10 µL. The UV detector was set at a wavelength of 270 nm for the detection. Column oven was set 
at 30±1 oC and the run time was 25 minutes. 
 
2.3 Tablet formulation 
Tablets were prepared by compression after wet granulation with Clit compression machine (Chamunda Pharma 
Machinery Private Limited, Ahmedabad, Gujarat; India). Model tablets containing 150 mg lamivudine and 300 
mg zidovudine. Microcrystalline cellulose, Solutab (Croscamellose Sodium), Magnesium Stereate and Aerosil 
(Colloidal Silicon Dioxide) were the excepients.  
Samples were analysed using the developed RP-HPLC method. The results were reported as means ± S.D 
(standard error of the mean). Results were statistically analysed for significant differences. 
2.4 Validation Parameters 
The validation exercise was performed as per ICH guidelines. It is applicable for the analysis of Lamivudine, 
Zidovudine and related impurities in combined oral dosage forms. 
Specificity: This was performed by injecting 10 µL aliquot of the Mobile phase (diluent), Placebo solution, 
diluent spiked separately with zidovudine related impurity C standard, Lamivudine working standard, 
Lamivudine salicylic acid, Zidovudine working standard, and Zidovudine related impurity B working standard..  
System suitability test was determined by making six replicate injections of the standard solution. The respective 
peak responses and the RSD for six replicate injections were recorded. The retention time, RSD of relative peak 
areas were recorded and are represented in Table 1. A sample chromatograms are shown in Figure 1 to 5. 
 
Forced degradation and Selectivity: lamivudine, zidovudine and placebo were incubated separately in 2M HCl, 
2M NaOH, 30 % H2O2 and at a temperature of 105oC for a period of 48 hrs. 10 µL aliquot of the product were 
injected.  Each degradant was tagged as related impurities to the mother API from which they were generated. 
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Mixture of the degradation product spiked with known USP related impurity standards were also analysed. 
Relative retention times of each peaks was observed relative to zidovudine in the degraded mixture.  
 
The precisions were determined by evaluating Repeatability (intraday precision) and Intermediate precision 
(interday precision). Intraday precision was determined by preparation and analysis of the same sample (all 
known standards and placebo) in six replicates. This was evaluated at various time points (0 (initial), 4, 8,12, 16, 
20 and 24 hours) by the same analyst. Interday precision was performed in six replicates at intervals of one day 
by two different analysts over a period of six days. The Percentage contents and relative standard deviation 
(RSD) were determined in each case. The results were subjected to statistical analysis at 95 % confidence 
interval to determine any significant differences. 
 
Accuracy was determined using the method of spiking. Six different amounts corresponding to 80 %, 100 % and 
120 % concentrations of zidovudine related impurity C, Lamivudine, Lamivudine salicylic acid, Zidovudine, and 
Zidovudine related impurity B working standard and placebo were analysed. The nominal concentrations were 
compared to the actual concentrations and the percentage recoveries were noted. The results were subjected to 
statistical analysis at 95% confidence interval to determine any significant differences. 
 
The stability of mixture of zidovudine related impurity C, Lamivudine, Lamivudine salicylic acid, Zidovudine, 
Zidovudine related impurity B working standard and placebo all dissolved in the diluent were evaluated. The 
prepared solution was kept at ambient temperature (25oC±2 oC) and analyzed at various time points (0 (initial), 3, 
6, 9, 24 hours). The responses were compared with those of freshly prepared solution and analysed statistically.  
 
Linearity and Working Concentration range, LOD and LOQ were determine for Zidovudine related impurity C, 
Lamivudine, salicylic acid, Zidovudine and Zidovudine related impurity B. 
 
Robustness was determined by making deliberate changes to the following parameters; flow rate, mobile phase 
composition and the pH of the mobile phase. Temperature and column were also changed. Results obtained were 
subjected to statistical analysis. 
2.5 Application of Proposed Method for the Analysis of Tablet Formulation 
Twenty tablets were weighed, the average weight was noted and powdered. Samples of the powdered tablet 
equivalent to 48 mg of lamivudine and 98 mg of zidovudine were weighed and transferred into a 100 mL 
volumetric flask. 60 mL of the diluent was added and sample sonicated for 5 minutes. Solution was made to 
volume with the diluent.  
The standard solution was prepared by weighing 48.5 mg of Lamivudine and 97.9 mg of zodovudine working 
standards into a 100 mL volumetric flask. 60 mL of the diluent was added and sample sonicated for 5 minutes. 
Solution was made to volume with the diluent 
Approximaly 0.0124 mg/mL of Zidovudine related compound C, lamivudine salicylic acid and Zidovudine 
related compound was prepared for the analysis. 
The peak areas in the tablet samples were compared to that of the standard and their percentage contents 
recorded. 
 
3. RESULTS AND DISCUSSION  
To develop a relatively simple system, Acetonitrile (HPLC grade) and Triethylamine were used as the only 
organic solvent with buffer (Buffer (0.0680 g of Potassium Dihydrogen Orthophosphate, 0.3 mL of 
Triethylamine, pH adjusted to 8.0 with Orthophosphoric acid to a final volume preparation of 100 mL) 
Various mobile phase acetonitrile to buffer in the ratios 40:60, 20:80 and 10:90 were used. Mobile composition 
which gave better resolution was observed to be 10(Acetonitrile):80 (buffer). 
Phenomenex Luna 5-µm C18 (2)-(250 x 4.6-mm, 5-µm) as the stationary phase was adopted and used for the 
analysis.  
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A wave length of 270 nm was adopted for appreciable peak area for the analyte. A flow rate of 1mL/min, run 
time of 25 minutes, injection volume of 10 µL and a column oven temperature of 30 oC were adopted for the 
analysis. 
 
3.1 Method Development 
3.2 Method Validation  
In evaluating specificity, there were no interferences. Injections of the placebo and the mobile phase (diluent) 
gave no peaks. Mean retention times are shown in table 1. 
Table 1: Results of specificity 
No Solution Mean retention time (minutes) 
1 Diluent no peak 
2 Placebo no peak 
3 Zidovudine related impurity C 3.769±0.004 
4 Lamivudine 4.855±0.013 
5 Lamivudine salicylic acid 15.532±0.064 
6 Zidovudine 21.001±0.076 
7 Zidovudine Related impurity B 23.282+0.011 
 
 
Fig. 1: Sample Chromatogram of blank Injection 
 
Fig. 2: Sample Chromatogram of placebo Injection 
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Fig. 3: Sample Chromatogram of placebo spiked with API and know related impurities 
 
In evaluating the degraded product and selectivity of the method, there were no interferences from unidentified 
peaks formed during the degradation process. . Injections of the placebo and the mobile phase (diluent) gave no 
peaks. The relative retention time (RRT) for each peak was calculate relative to zidovudine in the degraded 
standard mixed placebo spiked related impurity mixture. Refer to table 2 for relative retention times and Fig 4 
and Fig 5 for chromatograms. 
Table 2: Relative retention times for known and unknown compounds 
No Name RRT 
1 Lamivudine Related Compound 0.15 
2 Lamivudine Related Compound 0.17 
3 Zidovudine Related Compound C 0.18 
4 Lamivudine 0.23 
5 Lamivudine Related Compound 0.30 
6 Zidovudine Related Compound 0.39 
7 Lamivudine Related Compound 0.59 
8 Zidovudine Related Compound 0.63 
9 Lamivudine Salicylic acid 0.74 
10 Zidovudine 1.00 
11 Zidovudine Related Compound B 1.11 
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Fig. 4: Sample Chromatogram of degraded mixture of placebo, lamivudine and zidovudine 
 
Fig. 5: Sample Chromatogram of degraded mixture of placebo, lamivudine and zidovudine spiked with USP 
related compound standard. 
The % RSD obtained for Repeatability and reproducibility using the four known standards with placebo were in 
the range of 0.15 - 0.80 and 0.01- 0.44 respectively.  The method is of high precision since % RSD were less 
than 1.00 %. 
 
Table 3: Repeatability (Intraday precision) over study period of 24 Hours 
  
Zidovudine related 
compound c Lamivudine 
Lamivudine 
Salicylic 
acid 
Zidovudine 
Zidovudine 
related compound 
B 
Mean 
Recovery 100.25±0.15 100.51±0.81 100.13±0.34 99.82 ± 0.50 99.64±0.39 
% RSD 0.15 0.80 0.34 0.51 0.39 
 
Table 4: Reproducibility (intermediate precision) by First analyst over a period of Six days. 
  
Zidovudine related 
compound c Lamivudine 
Lamivudine 
Salicylic acid Zidovudine 
Zidovudine related 
compound B 
Mean 
Recovery 100.21±0.35 99.43±0.43 99.95±0.33 
100.29         
± 0.50 99.83±0.17 
% RSD 0.25 0.44 0.33 0.5 0.17 
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Table 5: Reproducibility (intermediate precision) by second analyst over a period of Six days. 
 
Zidovudine related 
compound c Lamivudine 
Lamivudine 
Salicylic acid Zidovudine 
Zidovudine related 
compound B 
Mean 
Recovery 100.11±0.23 99.41±0.14 99.99±0.01 
100.09        
± 0.70 100.01±0.04 
% RSD 0.23 0.14 0.01 0.7 0.04 
 
Analysis of variance (ANOVA) performed at 95 % confidence interval reveals that there were no statistically 
reliable difference between the amounts recovered for the various active compounds analysed during the intraday 
and intermediate precision testing.  P value observed were greater than 0.05, (p > 0.05). 
 
The accuracy of the recovery studies proves the quantification of target compounds within the acceptable limits. 
The percentage recovery were found to be in the range of 99.58 % - 100.53 %. Analysis of variance performed at 
95 % confidence interval reveals that there were no significant differences between the results obtained at the 
various concentration levels. P value observed were greater than 0.05, (p > 0.05). 
Table 6: Mean Recovery at different concentration level. 
Mean 
Recovery 
Zidovudine related 
compound c Lamivudine 
Lamivudine 
Salicylic acid Zidovudine 
Zidovudine related 
compound B 
80% 100.01±0.12 99.89±0.11 99.99±0.14 100.13         
± 0.21 100.11±0.11 
100% 99.91±0.22 99.91±0.21 100.10±0.12 99.95         
± 0.42 99.87±0.21 
120% 100.21±0.35 100.32±0.13 100.03±0.12 
99.58         
± 0.10 100.53±0.21 
Stability studies of solution containing mixture of zidovudine related impurity C, Lamivudine, Lamivudine 
salicylic acid, Zidovudine, Zidovudine related impurity B working standard and placebo were studied within a 
period of 24 hours. Statistical analysis performed on each analyte after the 24 hour period shows that there were 
no statistical reliable difference in the recovery of sample at 95 % confidence interval. P value obtained in each 
case were > 0.05.  
Table 7: Results of % Stable analyte in sample solution over a study period of 24 Hours 
storage 
time(hours) 
Zidovudine related 
compound c Lamivudine 
Lamivudine 
Salicylic acid Zidovudine 
Zidovudine related 
compound B 
0 99.91±0.22 99.91±0.21 100.10±0.12 99.95 ± 0.42 99.87±0.21 
4 99.99±0.26 100.0±0.31 99.10±0.23 99.99 ± 0.54 99.99±0.32 
8 100.09±0.12 98.95±0.23 99.00±0.41 100.0 ± 0.62 99.45±0.13 
12 100.11±0.03 99.95±0.34 98.03±0.52 99.67 ± 0.54 99.58±0.10 
16 98.9±0.63 99.45±0.14 98.00±0.82 99.12 ± 0.34 99.41±0.64 
24 99.9±0.63 99.45±0.14 98.00±0.82 99.98 ± 0.10 99.42±0.23 
 
Linearity and Working Concentration range, LOD and LOQ were determine for Zidovudine related impurity C, 
Lamivudine, Lamivudine salicylic acid, Zidovudine and Zidovudine related impurity B. The working 
concentration ranges from 0.0088 mg/mL to 0.0204 mg/mL for Zidovudine related impurity C, 0.0962 mg/mL to 
0.7699 mg/mL  for Lamivudine, 0.0087 mg/mL to 0.0204 mg/mL for Lamivudine salicylic acid, 0.1927 mg/mL 
to 1.5410 mg/mL for zidovudine and  0.0088 mg/mL to 0.0204 mg/mL for Zidovudine related impurity B. The 
Correlation co-efficient were observed to be 0.9975, 0.9997, 0.9983, 0.9991 and 0.9999 respectively. With 
regards to residual plot, the residuals were randomly dispersed. 
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Fig. 6: Calibration curve for zidovudine related       Fig. 7: Calibration curve for Lamivudine                                                                                                              
 compound C                        
 
 
 
Fig 8: Calibration curve for lamivudine salicylic      Fig 9: Calibration curve for Zidovudine 
     acid 
 
 
Fig 10: Calibration curve for Zidovudine related compound B 
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Table 8: Linear regression data, LOQ and LOD for calibration curves 
API 
Zidovudine 
related 
compound C 
Lamivudine Lamivudine Salicylic acid Zidovudine  
Zidovudine 
related 
compound B 
Concentration range 
(mg/mL) 0.0088 to 0.0204 
0.0962 to 
0.7699 
0.0087 to 
0.0204 
0.1927 to 
1.5410 0.0088 to 0.0204 
slope 36297 22052 3028 18831 22457 
Intercept -7.7729 113 -4.4497 186 -12.124 
Correlation 
coefficient 0.9975 0.9997 0.9983 0.9991 0.9999 
LOD(mg/mL) 1.12E-04 1.80E-04 1.44E-03 2.69E-04 1.67E-04 
LOQ(mg/mL) 3.40E-04 5.45E-04 4.36E-03 8.15E-04 5.07E-04 
With deliberate changes made to flow rate, pH of Mobile phase composition and temperature, the % RSD were 
observed to be in the range of 0.01 – 0.92.   
Column deliberately changed to 10 µm could not resolve all the test standards due to overlap of peaks. However, 
lamivudine and zidovudine were well resolved. Phenomenex Luna C18 (2) 250 x 4.6-mm, 10-µm) can therefore 
not be used for routine analysis of Zidovudine related impurity C, Lamivudine, Lamivudine salicylic acid, 
Zidovudine and Zidovudine related impurity B.   
Deliberate change of flow rate from 1.0 minutes to 2.0 minutes using Phenomenex Luna C18 (2) 250 x 4.6-mm, 
10-µm reduced the analysis time of lamivudine and zidovudine from 8 minutes to 4.0 minutes. Refer to fig: 11 
and Fig 12. 
Table 9: Changed factors and recovery for Robustness of method. 
Change Factors level 
Zidovudine 
related compound 
c  
Lamivudine Lamivudine Salicylic acid Zidovudine 
Zidovudine related 
compound B 
Flow Rate 
0.8 mL/min -2 99.95±0.21 99.34±0.33 100.22±0.31 99.34 ± 0.53 99.21±0.23 
1.0 mL/min 0 99.91±0.22 99.91±0.21 100.10±0.12 99.95 ± 0.42 99.87±0.21 
1.2 mL/min 2 99.45±0.53 100.31±0.32 99.90±0.62 100.32 ± 0.51 100.04±0.11 
pH 
7.8 -2 99.30±0.31 100.23±0.13 100.01±0.01 99.12 ± 0.43 99.31±0.43 
8 0 99.91±0.22 99.91±0.21 100.10±0.12 99.95 ± 0.42 99.87±0.21 
8.2 2 99.71±0.33 100.01±0.12 99.21±0.65 100.04 ± 0.42 100.23±0.32 
Mobile phase composition 
Buffer (pH 
8.0):Acetonitrile 88:12 99.32±0.71 100.01±0.45 100.51±0.65 99.98 ± 0.6.7 99.80±0.45 
Buffer(pH 
8.0):Acetonitrile 90:10 99.91±0.22 99.91±0.21 100.10±0.12 99.95 ± 0.42 99.87±0.21 
Buffer(pH 
8.0):Acetonitrile 92:8 99.98 ±0.31 100.45±0.43 100.54±0.32 99.43 ± 0.54 99.41±0.92 
Temperature 
25 OC -5 99.82±0.54 99.91±0.34 100.04±0.52 99.78 ± 0.47 99.89±0.11 
30 OC 0 99.91±0.22 99.91±0.21 100.10±0.12 99.95 ± 0.42 99.87±0.21 
35 OC 5 99.78±0.65 99.91±0.54 99.97±0.15 99.45 ± 0.78 98.98±0.34 
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Table 9: Continuation of Changed factors and recovery for Robustness of method 
Change 
Factors level 
Zidovudine 
related 
compound c  
Lamivudine Lamivudine Salicylic acid Zidovudine 
Zidovudine 
related 
compound B 
column 
Phenomenex 
Luna C18 (2) 
250 x 
4.6-mm, 
5-µm) 
99.91±0.22 99.91±0.21 100.10±0.12 99.95 ± 0.42 99.87±0.21 
Phenomenex 
Luna C18 (2) 
250 x 
4.6-mm, 
10-µm) 
 - 99.83±0.67 -   99.98 ± 0.89 -  
 
 
Table 10: Elution time at different flow rate with different columns. 
 
Lamivudine Zidovudine 
1.0 mL/min 2.0 mL/min 1.0 mL/min 2.0 mL/min 
Phenomenex Luna C18 (2) 
250 x 4.6-mm, 5- µm) 4.855±0.013 - 21.001±0.076 - 
Phenomenex Luna C18 (2) 
250 x 4.6-mm, 10-µm) 2.821±0.023 1.790±0.067 7.432±0.056 4.782±0.176  
 
Fig. 11: Sample Chromatogram of lamivudine and zidovudine using Phenomenex Luna 10-µm C18 (2)-250 x 
4.6-mm, 10-µm at a flow rate of 1.0 mL/min. 
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Fig. 12: Sample Chromatogram of lamivudine and zidovudine using Phenomenex Luna 10-µm C18 (2)-250 x 
4.6-mm, 10-µm at a flow rate of 2.0 mL/min. 
 
The mean recovery of Zidovudine related compound c, Lamivudine, Lamivudine Salicylic acid, Zidovudine and 
Zidovudine related compound B in the formulated tablet were quantified as per the method developed. Refer to 
table 11 for percentage recovery. 
 
Table 11: Mean Percentage recovery of lamivudine, zidovudine and known related impurities in formulated 
tablet. 
Zidovudine related 
compound c Lamivudine 
Lamivudine 
Salicylic acid Zidovudine 
Zidovudine related 
compound B 
0.0123±0.000133 99.87±0.23 0.00341±0.000014 100.01 ± 0.34 0.0045 ± 0.000012 
 
4. CONCLUSION  
The proposed RP-HPLC method for the estimation of Zidovudine related compound c, Lamivudine, Lamivudine 
Salicylic acid, Zidovudine and Zidovudine related compound B in model tablets and API was validated as per 
ICH guidelines. The method was found to be specific, robust, accurate and precise for the estimation of 
Zidovudine related compound c, Lamivudine, Lamivudine Salicylic acid, Zidovudine and Zidovudine related 
compound B in the fixed oral dosage tablets over the concentration ranges of 0.0204 mg/mL-0.0088mg/mL, 
0.0962 mg/mL-0.7699 mg/mL, 0.1929 mg/mL-1.5410 mg/mL and 0.0088 mg/mL-0.024 mg/mL respectively. 
LOD in order of the above stated active compounds were observed to be 1.12x10-4 mg/mL, 1.8 x10-4 mg/mL, 
1.44 x10-3 mg/mL, 2.69 x10-4 mg/mL and 1.67 x10-4 mg/mL. LOQ in the same order were 3.40x10-4 mg/mL, 
5.45 x10-4 mg/mL, 4.36 x10-3 mg/mL, 8.15x10-4 mg/mL and 5.07x10-4 mg/mL. 
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